Keyphrases
Gastroesophageal Adenocarcinoma
100%
Leptin
66%
Tumor Expression
66%
Chemotherapy Resistance
66%
EGFR Blockade
33%
Epidermal Growth Factor Receptor Gene
33%
Quality Performance Indicators
33%
Copy number Aberrations
33%
Gene Copy number
33%
Testicular Cancer
33%
Gefitinib
33%
Improved Outcomes
33%
Esophageal Cancer
33%
Epidermal Growth Factor Receptor
27%
Patient-derived Xenograft
16%
Placebo
15%
In Situ Hybridization
15%
Copy number Gain
14%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
14%
MTOR Inhibitor
11%
EGFR Inhibitors
11%
Preclinical Trials
11%
Confidence Interval
9%
Hazard Ratio
9%
Tumor
9%
Overall Survival
9%
Durable Response
8%
Healthcare Performance
8%
Malignancy
8%
Developed Countries
8%
Scotland
8%
Cancer Outcomes
8%
Limited Disease
8%
Advanced Disease
8%
Demographic Data
8%
Young Males
8%
KRAS mutation
6%
Esophagus Cancer
6%
Cancer Patients
6%
EGFR mutation
6%
BRAF mutation
6%
PIK3CA mutation
6%
Foundation Medicine
5%
EGFR Inhibition
5%
EGFR Amplification
5%
Co-amplification
5%
Anti-EGFR Agents
5%
Poor Prognosis
5%
Patient Cohort
5%
Novel Mechanism
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
73%
Chemotherapy
69%
Leptin
66%
Malignant Neoplasm
66%
Epidermal Growth Factor Receptor
66%
Esophageal Adenocarcinoma
66%
Esophagus Cancer
33%
Testis Cancer
33%
Gefitinib
33%
Adenocarcinoma
33%
Diseases
16%
Placebo
11%
Overall Survival
7%
Medicine and Dentistry
Neoplasm
74%
Leptin
66%
Esophageal Adenocarcinoma
66%
Malignant Neoplasm
66%
Esophageal Cancer
33%
Testis Cancer
33%
Gene Dosage
33%
Receptor Gene
33%
Gefitinib
33%
Epidermal Growth Factor Receptor
33%
Diseases
16%
Fluorescence in Situ Hybridization
12%
Placebo
12%
Cancer
8%
Hazard Ratio
7%
Overall Survival
7%
Esophageal Cancer
5%